SHANGHAI, China , and GAITHERSBURG, MD ., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences

- Oral presentation will highlight the potent anti-tumor effects demonstrated by TJ210, a novel antibody that blocks C5aR by binding to a unique epitope SHANGHAI and GAITHERSBURG, Md. , Oct. 27, 2020 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company

- Poster presentation highlights data from the U.S. phase 1 trial of lemzoparlimab, a highly differentiated anti-CD47 monoclonal antibody, for treatment of relapsed or refractory malignancy SHANGHAI and GAITHERSBURG, Md. , Oct. 15, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a

- Eftansomatropin, a long acting recombinant human growth hormone (rhGH) ready for Phase 3 Clinical Trial in China SHANGHAI and GAITHERSBURG, Md. , Sept. 30, 2020 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery,

- First international multi-center clinical trial (IMCT) of lemzoparlimab in China   - Second IND approval from China NMPA for lemzoparlimab SHANGHAI and GAITHERSBURG, Md. , Sept. 21, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to

Phase 1 Clinical Study Expected to Start in Q4 2020 PLANEGG/ MUNICH, Germany and SHANGHAI, China , Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced that the U.S.

SHANGHAI and GAITHERSBURG, Md. , Sept. 8, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in

Ordinary Share Purchase price equivalent to $33.00 per ADS, at a premium to the 30-day volume weighted average price ("VWAP")   Demonstrates leading biotech investors' strong endorsement of I-Mab's R&D innovation and value generation capabilities SHANGHAI and GAITHERSBURG, Md. , Sept.

AbbVie and I-Mab to collaborate on development and commercialization of I-Mab's highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)   I-Mab to receive upfront payment of $180 million   Potential to explore combination therapies with I-Mab's lemzoparlimab and AbbVie's venetoclax

Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and pharmacokinetics in cancer patients Joined the global effort against COVID-19 with plonmarlimab (TJM2) study which represents the first double-blind, placebo-controlled study